Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 2370 for:    "Liver Neoplasms"

Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03146637
Recruitment Status : Recruiting
First Posted : May 10, 2017
Last Update Posted : September 2, 2019
Sponsor:
Collaborator:
Beijing 302 Hospital
Information provided by (Responsible Party):
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.

Brief Summary:
This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for liver cancer.

Condition or disease Intervention/treatment Phase
Advanced Liver Cancer Biological: Activated CIK and bispecific antibody Biological: Activated CIK Phase 2

Detailed Description:
Liver cancer is one of the most common malignancies in our country, ranking fourth in all malignant tumors and third in mortality. Immunetherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single-center, randomized (1:1of targeted activation CIK and traditional CIK therapy )comparison clinical trial of activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody for advanced liver cancer. The investigators plan to recruit for 30 pairs of (60 cases) patients with advanced liver cancer, one of the two group will receive treatment of activated CIK, and the other receive mixed liquor of activated CIK and anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody. The result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a phase II clinical trial of single-center, randomized (1:1of targeted activation CIK and traditional CIK therapy ).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were randomly assigned to two groups,receive activated CIK or activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody,every participant has a unique identification number and emergency letter which have the information of group.
Primary Purpose: Treatment
Official Title: Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer
Actual Study Start Date : May 1, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer

Arm Intervention/treatment
Experimental: Activated CIK and bispecific antibody
activated CIK and Bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
Biological: Activated CIK and bispecific antibody
CIK cells was activated by inhibitor and bispecific antibody of anti-CD3/MUC1/CEA/EpCAM/GPC3

Active Comparator: Activated CIK
activated CIK
Biological: Activated CIK and bispecific antibody
CIK cells was activated by inhibitor and bispecific antibody of anti-CD3/MUC1/CEA/EpCAM/GPC3

Biological: Activated CIK
CIK cells was activated




Primary Outcome Measures :
  1. OS [ Time Frame: 3 years ]
    Overrall survival.The time of patient from randomization to death caused by any cause.


Secondary Outcome Measures :
  1. PFS [ Time Frame: 3 years ]
    Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause.

  2. TTP [ Time Frame: 1 years ]
    Time tumor progression.The time of patient from randomization to objective progress of the tumor.

  3. DCR [ Time Frame: 1 years ]
    Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease.

  4. ORR [ Time Frame: 1 years ]
    Objective response rate.The proportion of patients who had a best response rating of complete response and partial response.

  5. SRR [ Time Frame: 1 years ]
    Symptom remission rate. The proportion of symptoms are alleviated in all evaluative cases.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18-75 years old;
  2. The patient is diagnosed as advanced liver cancer,MUC1/CEA/EpCAM/GPC3 is positive;
  3. There is at least one tumor should be measured,and length≥10mm of focus not at lymph node or length≥10mm of focus at lymph node;
  4. C interval of BCLC;
  5. The patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or local therapies;
  6. Child-Pugh Score ≤7;
  7. If the patient received adjuvant chemotherapy after local treatment,the time should be more than 4 weeks after the end of chemotherapy, and disease progression or metastasis patients can also assigned into the group;
  8. The time of surgical treatment≥ 3 months ;At the end of the intervention, radiotherapy and the end of the ablation time is more than 4 weeks;
  9. The expected survival time ≥12 weeks;
  10. The patient did not took any antitumor drugs within two weeks(any antitumor drugs, Chinese patent medicine including Delisheng injection, Kanglaite injection, Aidi injection, huaier granule and Ganfule Pian);
  11. ECOG Score ≤1;
  12. HBV DNA<10^4copies/ml(2000IU/ml);
  13. Serum albumin≥28g/L,ALT and AST≤5.0×ULN,TBIL≤1.5×ULN, electrolyte is normal, proteinuria = 0 ~ 1 +, serum creatinine≤1.5 x ULN;
  14. Tests of blood,liver and kidney should meet the following criteria:WBC≥3×10^9/L,NEUT≥1×10^9/L,Hemoglobin ≥90 g/L,ANC≥1.5×109/L,PLT≥75×10^9/L;
  15. No serious disease are conflicts with the solution(such as autoimmune disease,immunodeficiency,orgen transplantation);
  16. Sign the informed consent;

Exclusion Criteria:

  1. Severe cirrhosis, medium or above ascites;
  2. Cancer embolus in the main portal vein and first branch, Hepatic duct and first branch, hepatic vein, inferior vena cava;;
  3. Patients of T cell lymphoma、myeloma,and patients are using immunosuppressant;
  4. Systemic autoimmune diseases, allergic constitution or immunocompromised patients.
  5. Patients of chronic diseases need immune stimulant or hormone therapy ;
  6. Patients of active bleeding or coagulant function abnormality(PT>16s、APTT>43s、TT>21s、INR≥2),and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy;
  7. Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test;
  8. Any significant clinical and laboratory abnormalities, the researchers think that affect the safety, such as: incontrollable active infection (> NCI - CTC AE v4.0 standard level 2), uncontrolled diabetes (> level 2 of NCI - CTC AE v4.0 ), hypertension and can't be controlled by two or less hypotensor(systolic pressure < 140 mmHg, diastolic pressure < 90 mmHg), grade II or above peripheral neuropathy (NCI CTC AE v4.0), grade II or above congestive heart failure (NCI CTC AE v4.0), myocardial infarction in 6 month, thyroid dysfunction (> level 2 of NCI - CTC AE v4.0), etc;
  9. Patients with brain、dura mater metastases or history of psychogeny;
  10. Gastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy;
  11. Patients with severe stomach/esophageal varices and need for intervention treatment;
  12. Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment;
  13. Patients with glomenrular filtration rate abnormal obviously(The endogenous creatinine clearance < 60 ml/min or serum creatinine > 1.5 x ULN);
  14. Positive for HIV antibody;
  15. Patients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay;
  16. Patients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment;
  17. Other reasons the researchers think not suitable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03146637


Contacts
Layout table for location contacts
Contact: Jiamin Cheng, Doctor +86-10-66933129 ext 6030 chengjiamin300@163.com

Locations
Layout table for location information
China, Beijing
302 Military Hospital of China Recruiting
Beijing, Beijing, China, 100039
Contact: Jiamin Cheng, Doctor    +86-10-66933129 ext 6030    chengjiamin300@163.com   
Principal Investigator: Yinying Lu         
Sub-Investigator: Zhen Zeng         
Sub-Investigator: Xuechun Lu         
Sub-Investigator: Jiamin Cheng         
Sub-Investigator: Zhengcheng Li         
Sub-Investigator: Jun Hou         
Sub-Investigator: Ting Zhang         
Sub-Investigator: Chunping Wang         
Sub-Investigator: Guanghua Rong         
Sub-Investigator: Bin Yang         
Sub-Investigator: Yan Chen         
Sub-Investigator: Ze Liu         
Sponsors and Collaborators
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Beijing 302 Hospital
Investigators
Layout table for investigator information
Study Director: Yinying Lu, Doctor Liver Cancer Diagnosis & Treatment and Research Center of 302 Military Hospital of China

Layout table for additonal information
Responsible Party: Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
ClinicalTrials.gov Identifier: NCT03146637     History of Changes
Other Study ID Numbers: BK2016.01
First Posted: May 10, 2017    Key Record Dates
Last Update Posted: September 2, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Clinical Study Report (CSR)
Time Frame: When the study is finished

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.:
Activated CIK
MUC1/CEA/EpCAM/GPC3
Bispecfic antibody
liver cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Liver Diseases
Antibodies
Immunoglobulins
Antibodies, Bispecific
Immunologic Factors
Physiological Effects of Drugs